buprenorphine
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Probuphine | DEVICE, IMPLANT | 74.2 mg | ||||
Belbuca | FILM, BUCCAL | 75 mcg, 150 mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg, 900 mcg | ||||
Butrans | FILM, EXTENDED RELEASE, TRANSDERMAL | 5 mcg/hr, 10 mcg/hr, 15 mcg/hr, 20 mcg/hr | ||||
Buprenex | SOLUTION, INJECTABLE | 0.3 mg/mL | ||||
Sublocade | SOLUTION, SUBCUTANEOUS | 100 mg/0.5 mL, 300 mg/1.5 mL | ||||
Subutex | TABLET, SUBLINGUAL | 2 mg, 8 mg |
ORDERED FORMULATION
FORMULARY INTERCHANGE*
buprenorphine (Buprenex)
nalBUPHine (Nubain)
*Interchange is for pain control indication only. When ordered for narcotic withdrawal, BUPRENEX should be dispensed as prescribed (NO SUB).
Belbuca is classified as non formulary. Interchange to a similar potency oral morphine ER tablet or solution. Use of Belbuca deferred to after patient discharge. Patients may utilize home supply of medication if deemed necessary while in the hospital.
Butrans patch is classified as non-formulary, not stocked. If needed, the patient should use his/her own supply. If the patient's own supply is not available, the physician should be contacted for other pain management options.
Sublocade is non-formulary, not stocked. Contact MD for alternative therapy. Defer to outpatient clinic use. Pain Center does not treat opiate use disorder/addiction.
Reviewed: October 25, 2011 (BUTRANS); December 17, 2013 (Subutex); 25 October 2016 (Probuphine); 22 May 2018 (Sublocade), 26 May 2020 (Belbuca)
REMS (Butrans): View FDA REMS Info
REMS (Probuphine): View FDA REMS Info
REMS (buprenorphine): Buprenorphine Transmucosal Products for Opioid Dependence (BTOD)Info
REMS (Sublocade): Sublocade (buprenorphine extended-release)
REMS (Subutex): Suboxone/Subutex (buprenorphine and naloxone/buprenorphine)
Belbuca medication guide
Butrans medication guide
Sublocade medication guide
Subutex medication guide